Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 28 to March 4, 2022. …
Subsequent Vaccination Cuts Risk for COVID-19 Reinfection
Vaccine effectiveness estimated at 82 percent for those aged 16 to 64 years, 60 percent for those aged 65 years or older
Vaccine Effectiveness Lower for Teens With Predominant Omicron
VE increased for adolescents aged 16 to 17 years at seven or more days after a third booster dose during omicron predominance
Homologous Pfizer-BioNTech Booster Safe for Adolescents
Reactions to booster occur with similar frequency as after receipt of second vaccine dose, generally mild to moderate
MIS-C Rare in 12- to 20-Year-Olds After COVID-19 Vaccination
Reporting rate was 1.0 case per million vaccinated individuals and 0.3 cases among those without evidence of SARS-CoV-2 infection
Vaccination Ups Infection-Acquired Immunity Against SARS-CoV-2
Two doses of BNT162b2 vaccine linked to high short-term protection against infection, which wanes after six months
Link Between COVID-19 Vaccination, Sudden Deafness Explored
Study conducted in U.S. suggests no population-level association; study conducted in Israel suggests increased risk with very small effect size
Vaccine Rollout Linked to Drop in Severe COVID-19 in Dialysis Patients
And, patients on maintenance dialysis who received COVID-19 vaccination had decreasing antibody titers over time
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 21 to 25, 2022. This …
COVID-19 Vaccination Tied to Decline in Distress in U.S. Adults
Decreases in distress and perceived risks for infection, hospitalization, and death reported by those receiving at least one dose of vaccine